Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

McKinsey
Merck
Boehringer Ingelheim
Moodys
Colorcon
Mallinckrodt

Last Updated: November 28, 2022

Details for Patent: 6,967,208


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


Which drugs does patent 6,967,208 protect, and when does it expire?

Patent 6,967,208 protects ELIQUIS and is included in one NDA.

This patent has seventy-four patent family members in thirty-six countries.

Summary for Patent: 6,967,208
Title: Lactam-containing compounds and derivatives thereof as factor Xa inhibitors
Abstract:The present application describes lactam-containing compounds and derivatives thereof of Formula I: ##STR1## or pharmaceutically acceptable salt forms thereof, wherein ring P, if present is a 5-7 membered carbocycle or heterocycle and ring M is a 5-7 membered carbocycle or heterocycle. Compounds of the present invention are useful as inhibitors of trypsin-like serine proteases, specifically factor Xa.
Inventor(s): Pinto; Donald J. P. (Churchville, PA), Quan; Mimi L. (Yardley, PA), Orwat; Michael J. (New Hope, PA), Li; Yun-Long (Wilmington, DE), Han; Wei (Yardley, PA), Qiao; Jennifer X. (Princeton, NJ), Lam; Patrick Y. S. (Chadds Ford, PA), Koch; Stephanie L. (Newark, DE)
Assignee: Bristol-Myers Squibb Pharma Company (Princeton, NJ)
Application Number:10/245,122
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 6,967,208
Patent Claim Types:
see list of patent claims
Compound; Composition; Use;

Drugs Protected by US Patent 6,967,208

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Bristol Myers Squibb ELIQUIS apixaban TABLET;ORAL 202155-001 Dec 28, 2012 AB RX Yes No See Plans and Pricing See Plans and Pricing Y Y PROPHYLAXIS OF DEEP VEIN THROMBOSIS AND PULMONARY EMBOLISM See Plans and Pricing
Bristol Myers Squibb ELIQUIS apixaban TABLET;ORAL 202155-001 Dec 28, 2012 AB RX Yes No See Plans and Pricing See Plans and Pricing Y Y REDUCING THE RISK OF STROKE AND SYSTEMIC EMBOLISM See Plans and Pricing
Bristol Myers Squibb ELIQUIS apixaban TABLET;ORAL 202155-001 Dec 28, 2012 AB RX Yes No See Plans and Pricing See Plans and Pricing Y Y TREATMENT OF PULMONARY EMBOLISM (PE) See Plans and Pricing
Bristol Myers Squibb ELIQUIS apixaban TABLET;ORAL 202155-001 Dec 28, 2012 AB RX Yes No See Plans and Pricing See Plans and Pricing Y Y REDUCE THE RISK OF RECURRENT DEEP VEIN THROMBOSIS (DVT) See Plans and Pricing
Bristol Myers Squibb ELIQUIS apixaban TABLET;ORAL 202155-001 Dec 28, 2012 AB RX Yes No See Plans and Pricing See Plans and Pricing Y Y REDUCE THE RISK OF RECURRENT PULMONARY EMBOLISM See Plans and Pricing
Bristol Myers Squibb ELIQUIS apixaban TABLET;ORAL 202155-001 Dec 28, 2012 AB RX Yes No See Plans and Pricing See Plans and Pricing Y Y TREATMENT OF DEEP VEIN THROMBOSIS (DVT) See Plans and Pricing
Bristol Myers Squibb ELIQUIS apixaban TABLET;ORAL 202155-001 Dec 28, 2012 AB RX Yes No See Plans and Pricing See Plans and Pricing Y Y PROPHYLAXIS OF DEEP VEIN THROMBOSIS (DVT) See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 6,967,208

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 037092 See Plans and Pricing
Argentina 067965 See Plans and Pricing
Austria 439360 See Plans and Pricing
Austria 544750 See Plans and Pricing
Australia 2002341693 See Plans and Pricing
Australia 2008207537 See Plans and Pricing
Brazil 0212726 See Plans and Pricing
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Boehringer Ingelheim
Dow
Mallinckrodt
Medtronic
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.